Literature DB >> 12827452

A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.

Philippe Rostagno1, Jeanine Gioanni, Eliane Garino, Pierre Vallino, Moise Namer, Marc Frenay.   

Abstract

A mutation analysis of the BRCA1 gene in 140 French families with a history of breast cancer or breast-ovarian cancer revealed several deleterious germline mutations, as well as rare sequence variants. The 19 genetics variants were of 15 different types, two of which had not been reported in the Breast cancer Information Core (BIC) database. Five distinct truncating mutations, leading to putative nonfunctional proteins, were identified out of 140 index cases (3.5%). One novel nonsense mutation, C4491T, was reported, whereas the four other BRCA1 deleterious mutations identified consisted of frequent frameshifts in the nucleotide sequence. One splice variant (331+3A>G) and thirteen missense variations leading to amino acid substitutions of unknown structural and functional importance were identified. Among these, two BRCA1 missense mutations, A120G and T243C could be considered as suspected deleterious. The first missense mutation modified the initiation codon (M1V) and the second (C39R) may have consequences on the structure and functioning of the BRCA1 protein by modifying cysteine ligands from the RING finger domain. As expected BRCA1 gene alteration, including missense mutations of unknown biological significance, were more frequent in families with a history of breast-ovarian-cancer (32%) than in breast-cancer-only families (12%).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827452     DOI: 10.1007/s10038-003-0038-y

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  23 in total

1.  Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group.

Authors:  S E Antonarakis
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

2.  Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.

Authors:  M Cappelli; L Surh; L Humphreys; S Verma; D Logan; A Hunter; J Allanson
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

3.  Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.

Authors:  Deborah Thompson; Csilla I Szabo; Jon Mangion; Rogier A Oldenburg; Fabrice Odefrey; Sheila Seal; Rita Barfoot; Karin Kroeze-Jansema; Dawn Teare; Nazneen Rahman; Hélène Renard; Graham Mann; John L Hopper; Saundra S Buys; Irene L Andrulis; Ruby Senie; Mary B Daly; Dee West; Elaine A Ostrander; Ken Offit; Tamar Peretz; Ana Osorio; J Benitez; Katherine L Nathanson; Olga M Sinilnikova; Edith Olàh; Yves-Jean Bignon; Pablo Ruiz; Michael D Badzioch; Hans F A Vasen; Andrew P Futreal; Catherine M Phelan; Steven A Narod; Henry T Lynch; Bruce A J Ponder; Ros A Eeles; Hanne Meijers-Heijboer; Dominique Stoppa-Lyonnet; Fergus J Couch; Diana M Eccles; D Gareth Evans; Jenny Chang-Claude; Gilbert Lenoir; Barbara L Weber; Peter Devilee; Douglas F Easton; David E Goldgar; Michael R Stratton
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

4.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Authors:  S A Narod; J S Brunet; P Ghadirian; M Robson; K Heimdal; S L Neuhausen; D Stoppa-Lyonnet; C Lerman; B Pasini; P de los Rios; B Weber; H Lynch
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

5.  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.

Authors:  D Stoppa-Lyonnet; P Laurent-Puig; L Essioux; S Pagès; G Ithier; L Ligot; A Fourquet; R J Salmon; K B Clough; P Pouillart; C Bonaïti-Pellié; G Thomas
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  The breast cancer information core: database design, structure, and scope.

Authors:  C Szabo; A Masiello; J F Ryan; L C Brody
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Understanding missense mutations in the BRCA1 gene: an evolutionary approach.

Authors:  Melissa A Fleming; John D Potter; Christina J Ramirez; Gary K Ostrander; Elaine A Ostrander
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

9.  Genetic analysis of breast cancer in the cancer and steroid hormone study.

Authors:  E B Claus; N Risch; W D Thompson
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

Review 10.  The genetics of breast and ovarian cancer.

Authors:  D Ford; D F Easton
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  1 in total

Review 1.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.